Selenium speciation studies in cancer patients to evaluate the responses of biomarkers of selenium status to different selenium compounds.

ABSTRACT: This work presents the first systematic comparison of selenium (Se) speciation in plasma from cancer patients treated orally with three Se compounds (sodium selenite, SS; L-selenomethionine, SeMet; or Se-methylselenocysteine, MSC) at 400 µg/day for 28 days. The primary goal was to investigate how these chemical forms of Se affect the plasma Se distribution, aiming to identify the most effective Se compound for optimal selenoprotein expression. This was achieved using methodology based on HPLC-ICP-MS after sample preparation/fractionation approaches. Measurements of total Se in plasma samples collected before and after 4 weeks of treatment showed that median total Se levels increased significantly from 89.6 to 126.4 µg kg^-1 Se (p < 0.001), particularly when SeMet was administered

SUBMITTER: Del Castillo Busto ME 

PROVIDER: S-EPMC11009772 | biostudies-literature | 2024 May

REPOSITORIES: biostudies-literature